Moreover, both troglitazone (TZD) treatment and obesity decreased GPX1 and GPX3 protein levels in adipose tissue, being indicative of low contribution of adipose tissue GPX to serum GPX activity [172]. This evidence concerns the gene GPX1 and obesity due to melanocortin 4 receptor deficiency.